Samir Parekh, MBBS
img_Samir Parekh
PROFESSOR | Medicine, Hematology and Medical Oncology
PROFESSOR | Oncological Sciences
PROFESSOR | Immunology & Immunotherapy
Are you a patient?
Specialties
Cancer (Oncology), Hematology-Oncology
Research Topics
Computational Biology, Drug Resistance, Epigenetics, Lymphoma, Transcriptional Activation and Repression
Multi-Disciplinary Training Area
Cancer Biology [CAB], Disease Mechanisms and Therapeutics (DMT)
Mantle Cell Lymphoma (MCL)
MCL is a rare and incurable non-Hodgkins lymphoma whose pathogenesis is not clearly understood. The SOX11 transcription factor is overexpressed in the majority of Mantle cell lymphomas. We identified the direct DNA binding targets of SOX11 in several oncogenic pathways using ChIP-sequencing and functional genomics and have now developed an inducible mouse model of SOX11 overexpression that recapitulates the MCL phenotype. We are developing anti-SOX11 small molecules with structural biologist Dr. Aneel Aggarwal at Mount Sinai that could be applicable in MCL and other SOX11 expressing tumors like lung cancer, ovarian cancer and glioma.

Visit the Parekh Laboratory

Integrative Genomics for Drug repositioning in Myeloma
With the advent of next-generation sequencing, we have been systematically developing and studying the application of integrative genomics (including methylation, gene expression and exome sequencing) to guide personalized repurposing of FDA approved drugs to overcome chemotherapy resistance in B cell malignancies like non-Hodgkins Lymphoma and Multiple Myeloma. I have an ongoing IRB approved clinical trial for genomic signature guided therapeutic selection in collaboration with Drs. Jagannath and Schadt, Dean for Precision Medicine and the Jean C. and James W. Crystal Professor of Genomics at the Icahn School of Medicine at Mount Sinai.

MD, KJ Somaiya Medical College

Residency, Internal Medicine, John H Stroger Jr Hospital of Cook County

Fellowship, Hematology & Oncology, Montefiore/Albert Einstein College of Medicine Rheumatology

Certifications

American Board of Internal Medicine

2005

Young Investigator Award

ASCO

Young Investigator Travel Award

ECOG

First Overall and Highest Rank in General Internal Medicine

K.J. Somaiya Medical College

Publications

Selected Publications

Long-term remission after cilta-cel in multiple myeloma is linked to diverse T cells and low myeloid suppression. Junia Vieira dos Santos, David T. Melnekoff, Adolfo Aleman, Tarek H. Mouhieddine, Rocio Montes de Oca, Feng Wang, Sridevi Rajeeve, Sherry Bhalla, Oliver Van Oekelen, Bhaskar Upadhyaya, Yogita Ghodke-Puranik, Violetta Leshchenko, Seunghee Kim-Schulze, Adeeb Rahman, Shaked Afik, Hadas Lewinsky, Vicki Plaks, Santiago Thibaud, Hearn Jay Cho, Joshua Richter, Cesar Rodriguez, Larysa Sanchez, Adriana Rossi, Shambavi Richard, Ajai Chari, Deepu Madduri, Sundar Jagannath, Samir Parekh, Alessandro Laganà. Blood advances

Affinity-matured CD72-targeting nanobody CAR T cells enhance elimination of antigen-low B-cell malignancies. Adila Izgutdina, Tasfia Rashid, William C. Temple, Sarah Aminov, Bonell Patiño-Escobar, Sujata Walunj, Huimin Geng, Hiroyuki Takamatsu, Daniel Gil-Alós, Amrik S. Kang, Emilio Ramos, Szu Ying Chen, Haley Johnson, Matthew A. Nix, Akul Naik, Mingcheng Li, Constance M. Yuan, Hao Wei Wang, Srabani Sahu, Rebecca C. Larson, Christopher Carpenter, Fernando Salangsang, Paul Phojanakong, Juan Antonio Camara Serrano, Isa Tariq, Ons Zakraoui, Veronica Steri, Antonio Valeri, Joaquin Martinez-Lopez, Marcela V. Maus, Samir Parekh, Amit Verma, Nirali N. Shah, Arun P. Wiita. Journal for ImmunoTherapy of Cancer

SOX11 modulates BCR signaling through the PAX5/CD19 axis for therapeutic targeting in BTK-resistant mantle cell lymphoma. Rudra Prasad Dutta, Heng Huan Lee, Violetta V. Leshchenko, Ravi Prakash Shukla, Fangfang Yan, Yang Liu, H. Ümit Kaniskan, Xing Qiu, Jian Jin, Lapo Alinari, Michael Wang, Samir Parekh. Blood advances

View All Publications

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Below are financial relationships with industry reported by Dr. Parekh during 2025 and/or 2026. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership

  • Genentech, Inc.
  • GRAIL, Inc
  • Regeneron Pharmaceuticals, Inc.
  • Janssen Pharmaceuticals

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.